A reverse genetics approach for recovery of recombinant influenza B viruses entirely from cDNA.
The recovery of recombinant influenza A virus entirely from cDNA was recently described (9, 19). We adapted the technique for engineering influenza B virus and generated a mutant bearing an amino acid change E116G in the viral neuraminidase which was resistant in vitro to the neuraminidase inhibitor zanamivir. The method also facilitates rapid isolation of single-gene reassortants suitable as vaccine seeds and will aid further investigations of unique features of influenza B virus.
Jackson
David
D
University of Reading, Whiteknights, Reading RG6 6AJ. GlaxoSmithKline Medicine Research Centre, Stevenage SG1 2NY, United Kingdom.
Cadman
Andrew
A
Zurcher
Thomas
T
Barclay
Wendy S
WS
D003001:Cloning, Molecular; D018076:DNA, Complementary / Q000235:genetics*; D024882:Drug Resistance, Viral; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006146:Guanidines; D006801:Humans; D009981:Influenza B virus / Q000187:drug effects / Q000201:enzymology / Q000235:genetics*; D009154:Mutation; D009439:Neuraminidase / Q000037:antagonists & inhibitors / Q000235:genetics / Q000378:metabolism; D011714:Pyrans; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism; D011995:Recombination, Genetic; D020133:Reverse Transcriptase Polymerase Chain Reaction; D012794:Sialic Acids / Q000494:pharmacology; D053243:Zanamivir
D018076:DNA, Complementary; D004791:Enzyme Inhibitors; D006146:Guanidines; D011714:Pyrans; D012367:RNA, Viral; D012794:Sialic Acids; D009439:Neuraminidase; D053243:Zanamivir